| Current Price | $3.56 | Mkt Cap | $329.0M |
|---|---|---|---|
| Open | $3.52 | P/E Ratio | 0.00 |
| Prev. Close | $3.29 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $3.39 - $3.75 | Volume | 6,293,279 |
| 52-Wk Range | $2.95 - $3.75 | Avg. Daily Vol. | 1,299,151 |
A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.
| Current Price | $3.56 | Mkt Cap | $329.0M |
|---|---|---|---|
| Open | $3.52 | P/E Ratio | 0.00 |
| Prev. Close | $3.29 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $3.39 - $3.75 | Volume | 6,293,279 |
| 52-Wk Range | $2.95 - $3.75 | Avg. Daily Vol. | 1,299,151 |
The best Bull and Bear pitches based on recency and number of recommendations.
Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the business, their partnerships are solid and will be… More
I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky… More
Read the most recent pitches from players about INO.
Recs
zzlangerhans
(99.62)
Submitted: 4/5/2016 2:20:05 PM :
Start Price:
$9.88
NASDAQ:INO Score:
+123.55
I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky market for biotech given the company's long history of operations without any approved products and constantly-changing focus. Most of their current pipeline is in early stage trials and it will be a long time before the VGX-3100 phase III trial generates a significant catalyst. Cash of 183M is respectable but he quarterly burn is in the teens. This might not be an intuitive short but could be used as a counterweight for beloved long positions that are showing stretchmarks amid this spring sector rebound.
Recs
allstar31
(99.90)
Submitted: 9/12/2014 10:58:34 PM :
Start Price:
$10.40
NASDAQ:INO Score:
+132.31
Uses known stock promoter Redchip.com, for a pump and dump scheme. Garbage.
Recs
Ronbo69
(< 20)
Submitted: 7/22/2014 10:13:49 PM :
Start Price:
$13.87
NASDAQ:INO Score:
-140.68
How about a company with enough money to continue R&D work without any help from the big Pharma, Things are looking good going into results from Ph. II clinical, and with many other ongoing projects, eg. prostate research, things are very exciting.
Find the members with the highest scoring picks in INO.
InsiderAlerts (< 20) Score: +386.96
The Score Leader is the player with the highest score across all their picks in INO.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| BicaChica | 80.59 | 8/3/2009 |
|
5Y | $9.44 | -61.44% | +233.33% | +294.77 | 0 Comment | |
| epc53 | 27.66 | 7/31/2009 |
|
5Y | $8.48 | -57.08% | +235.68% | +292.75 | 0 Comment | |
| rhinomaj | 92.01 | 8/4/2009 |
|
3M | $8.36 | -56.46% | +231.70% | +288.16 | 0 Comment | |
| guru111melbourne | 73.45 | 11/24/2009 |
|
5Y | $6.20 | -41.29% | +198.50% | +239.79 | 0 Comment | |
| uconn777 | < 20 | 7/1/2010 |
|
5Y | $4.08 | -10.78% | +225.48% | +236.27 | 0 Comment | |
| bdg10 | < 20 | 1/12/2011 |
|
5Y | $5.84 | -37.67% | +158.16% | +195.83 | 0 Comment | |
| KidJones | 33.22 | 9/3/2013 |
|
5Y | $7.16 | -49.16% | +100.53% | +149.69 | 0 Comment | |
| rlm02002 | < 20 | 11/4/2013 |
|
5Y | $7.60 | -52.11% | +87.53% | +139.63 | 0 Comment | |
| BigShark | < 20 | 10/3/2014 |
|
3Y | $10.75 | -66.14% | +68.83% | +134.97 | 0 Comment | |
| LowEnterpriseVal | < 20 | 6/10/2014 |
|
5Y | $9.96 | -63.47% | +69.58% | +133.05 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
